---
title: Getting Investigational Drugs to Patients in Decentralized Clinical Trials
image: https://info.clario.com/hubfs/Social_1024x512On-DemandWebinar-DCT-IRT%20(1)-1.jpg
---

[![Gradient.png](https://cdn2.hubspot.net/hub/2500081/hubfs/Gradient/Branding/Gradient.png?width=2915&height=816&name=Gradient.png "Gradient.png")](https://inboundpixels-2500081.hs-sites.com/gradient-home)

- [Default HubSpot Blog](https://bioclinica-7229613.hs-sites.com/blog)

[![Clario_Logo_Neg_RGB_01_Trans_2150x695px](https://info.clario.com/hs-fs/hubfs/Clario_Logo_Neg_RGB_01_Trans_2150x695px.png?width=2150&height=695&name=Clario_Logo_Neg_RGB_01_Trans_2150x695px.png "Clario_Logo_Neg_RGB_01_Trans_2150x695px")](https://www.bioclinica.com/)

### WATCH WEBINAR

# DCTs: How to get investigational drugs to patients

 

**Speaker**

Susan Rizzo, Director, Service Delivery RTSM, Bioclinica Software Solutions

The COVID-19 pandemic has accelerated the adoption of decentralized clinical trials (DCTs), which was already increasing due to the benefits of convenience, greater access to treatments by patients, greater access to a more representative population by investigators and reduced burden on site staff. One of the challenges with remote visits is the distribution, tracking, reconciliation and destruction of the investigational medicinal product (IMP), while maintaining the blinding and patient confidentiality. To address this challenge, operational and technological strategies have been implemented in many trials. However, interactive response technology (IRT) solution also has a big role to play in any solution required to support DCTs, today and in the future.

**What you will learn:**

- The challenges of implementing direct-to-patient shipment of IMP
- The pros and cons of Implemented Strategies
- An outline of the key considerations for an IRT solution to support hybrid or full DCT implementations

 

© 2023 Clario